Medicine Research & Development Team

Dr. Brian Duff Sloley holds a Ph.D. in Biology from the University of Waterloo. He has over 35 years of experience in analytical research and product development, including positions at the University of Saskatchewan’s Neuropsychiatric Research Unit, Novokin Biotech, Sinoveda, and Radient Technologies. Dr. Sloley’s specialties include comparative neurobiology with a focus on neurotransmitter identification, metabolism, and disruption, as well as botanical composition. Dr. Sloley has extensive experience working in analytical biochemistry in a Good Laboratories Practice (GLP) setting, including HPLC, LCMS/MS, UV absorbance, and fluorescent detection. In his spare time, Dr. Sloley is an active member of the Alberta Mycological Society and will be instrumental in characterizing and discovering new potent compounds and sourcing novel fungi.

Dr. Kevin Morin is a psychiatrist and is currently site lead for the rTMS neuromodulation service at Alberta Hospital Edmonton (AHE). Dr. Morin also has an inpatient practice at AHE and has an outpatient practice at Precision NeuroClinics performing neuronavigated rTMS and research in Ketamine. He is an Assistant Clinical Professor in the Department of Psychiatry at the University of Alberta. He is an Adjunct Professor in the Faculty of Pharmacy and Pharmaceutical Sciences, where he has a pharmaco-EEG imaging and VR/AR laboratory at API. Dr. Morin’s pharmaco-EEG imaging expertise will be instrumental in enabling Mydecine to determine the potential activity of various extracted compounds on the brain in vitro.

Dr. Rakesh Bhat graduated magna cum laude from Leipzig University with a Ph.D. in bioanalytical chemistry, molecular biology, and biochemistry. Dr. Bhat has spent two decades working in translational research, including developing niche bioanalytical capacities such as a novel adult human ventricular cardiomyocyte cell line(s) stably expressing hERD and Nav1.5 using electrophysiology and other cell lines for a wide range of industry projects. In his previous role, Dr. Bhat worked under Nobel Laureate Michael Houghton. Dr. Bhat has extensive translational project management experience. As API’s director of laboratory services, Dr. Bhat will be the key member of the team facilitating and implementing Mydecine’s pre-clinical product development.

Dr. Raimar Löbenberg is an expert in the areas of pharmaceutics, drug development, and delivery. He is a member of the United States Pharmacopoeia (USP) expert committee for Dietary Supplements and Herbal Medicines and chair of the subcommittee for performance testing of dietary supplements, member of the American Association of Pharmaceutical Scientists (AAPS) Steering Committee for Drug Release and Dissolution, and vice-chair of Specialty Committee for Pharmaceutical Quality of Traditional Medicines of the World Foundation of Traditional Chinese Medicines, and a past president of the Canadian Society for Pharmaceutical Sciences. Dr. Löbenberg is serving as Mydecine’s expert in controlled substances, formulation, and GMP manufacturing.

Dr. Vijay Somayaji has over 30 years of combined academic and biotech industry experience in various areas, including research and development, product development, and quality assurance, and quality control. She obtained her Ph.D. in Chemistry from the Indian Institute of Science and did her post-doctoral work with Dr. H.C. Brown (Nobel Laureate) at Purdue University (USA). At the University of Alberta, she worked as a research associate with Dr. L.I. Wiebe (Faculty of Pharmacy and Pharmaceutical Sciences) before joining Biomira Inc. as a senior scientist. She has since worked as a manager of Product Development at AltaRex Corp., as a Director of Product Development at Novolytic Inc., as Director of Drug Development at Virexx Medical Corp., and as a Quality Assurance and Quality Control consultant for IMbiotechnologies Ltd. Dr. Somayaji is serving as QA/QC for Mydecine’s clinical manufacturing.

Dr. Antonio Bruni has over a decade of experience managing commercial research and development in industry and academia. He completed his B.Sci. Cum Laude at Lake Superior State University and a Ph.D. in experimental surgery under world-renowned clinician-scientist, Dr. James Shapiro, developer of the “Edmonton Protocol” at the University of Alberta, in addition to serving as quality coordinator for Dr. Shapiro’s trials. While working in the industry for Sernova Corp, Dr. Bruni co-authored Health Canada submissions for phase 1 and 2 clinical trials and managed Sernova’s product pipeline analysis. Dr. Bruni is serving as project manager for the team working on Mydecine’s DMF and IB.